Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

5HDO

Crystal structure of a nanobody raised against urokinase-type plasminogen activator

5HDO の概要
エントリーDOI10.2210/pdb5hdo/pdb
分子名称Anti-HCV NS3/4A serine protease immoglobulin heavy chain, SULFATE ION, CHLORIDE ION, ... (4 entities in total)
機能のキーワードimmune system
由来する生物種Camelus dromedarius (Dromedary)
タンパク質・核酸の鎖数4
化学式量合計54917.90
構造登録者
Kromann-Hansen, T. (登録日: 2016-01-05, 公開日: 2016-06-01, 最終更新日: 2024-11-13)
主引用文献Kromann-Hansen, T.,Oldenburg, E.,Yung, K.W.,Ghassabeh, G.H.,Muyldermans, S.,Declerck, P.J.,Huang, M.,Andreasen, P.A.,Ngo, J.C.
A Camelid-derived Antibody Fragment Targeting the Active Site of a Serine Protease Balances between Inhibitor and Substrate Behavior.
J.Biol.Chem., 291:15156-15168, 2016
Cited by
PubMed Abstract: A peptide segment that binds the active site of a serine protease in a substrate-like manner may behave like an inhibitor or a substrate. However, there is sparse information on which factors determine the behavior a particular peptide segment will exhibit. Here, we describe the first x-ray crystal structure of a nanobody in complex with a serine protease. The nanobody displays a new type of interaction between an antibody and a serine protease as it inserts its complementary determining region-H3 loop into the active site of the protease in a substrate-like manner. The unique binding mechanism causes the nanobody to behave as a strong inhibitor as well as a poor substrate. Intriguingly, its substrate behavior is incomplete, as 30-40% of the nanobody remained intact and inhibitory after prolonged incubation with the protease. Biochemical analysis reveals that an intra-loop interaction network within the complementary determining region-H3 of the nanobody balances its inhibitor versus substrate behavior. Collectively, our results unveil molecular factors, which may be a general mechanism to determine the substrate versus inhibitor behavior of other protease inhibitors.
PubMed: 27226628
DOI: 10.1074/jbc.M116.732503
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.16 Å)
構造検証レポート
Validation report summary of 5hdo
検証レポート(詳細版)ダウンロードをダウンロード

246905

件を2025-12-31に公開中

PDB statisticsPDBj update infoContact PDBjnumon